Gabapentin Withdrawal & Tapering Risks

Seizure Risk During Gabapentin Withdrawal

The most dangerous complication of gabapentin withdrawal is seizure activity, which can occur even in patients who have never had a seizure and were not prescribed gabapentin for epilepsy. Case reports published in the American Journal of Emergency Medicine, Epilepsy & Behavior, and other medical journals document generalized tonic-clonic seizures, status epilepticus (prolonged or repeated seizures requiring emergency intervention), and seizure-related injuries including falls, fractures, and head trauma occurring during gabapentin withdrawal. These seizures typically occur within 24 to 72 hours of abrupt discontinuation or rapid dose reduction.

The seizure risk is particularly dangerous because many gabapentin patients and their physicians do not anticipate it. Gabapentin has been marketed as a safe, non-addictive medication that can be easily started and stopped. This messaging leads patients to discontinue the drug abruptly — because they cannot refill a prescription, because they experience a coverage gap, or because they decide to stop on their own after learning about cognitive risks. Emergency departments have reported increasing presentations of gabapentin withdrawal seizures as prescribing volumes have grown, yet many emergency physicians still do not recognize gabapentin withdrawal as a seizure etiology, potentially leading to misdiagnosis and inappropriate treatment.

The Withdrawal Dilemma for Cognitive Decline Patients

Patients who discover that gabapentin may be causing their cognitive decline face an agonizing dilemma. They cannot simply stop taking the drug without risking seizures and other dangerous withdrawal complications. Yet every day they continue taking gabapentin, they accumulate additional cognitive exposure that may worsen their impairment. The medically recommended approach — a slow taper under physician supervision — can take weeks to months, during which the patient remains on a drug they now know is harming their brain. This forced continuation represents a distinct category of injury: the manufacturer's failure to warn about dependence risk trapped patients in a cycle of harm from which they cannot safely or quickly exit.

The tapering process itself can produce cognitive symptoms. As doses are reduced, patients frequently experience rebound anxiety, sleep disruption, and pain flares that can independently impair cognitive function. Some patients report temporary worsening of brain fog and memory difficulties during tapering, possibly reflecting the neurochemical instability of the withdrawal process. For patients already cognitively compromised by gabapentin, these additional insults during tapering represent compounded harm that should be factored into damages calculations.

Manufacturer's Failure to Warn About Dependence

For decades, gabapentin was marketed as a safe alternative to potentially addictive medications, particularly opioids and benzodiazepines. The prescribing information's withdrawal warnings were minimal and buried deep in the label, advising only that the drug should be tapered over at least one week. No prominent warnings about physical dependence, seizure risk upon discontinuation, or the potential need for extended tapering protocols were included. The manufacturer's own pharmacological knowledge — that gabapentin modulates calcium channel expression and alters inhibitory neurotransmission — should have led to more prominent dependence warnings, given that these mechanisms are well-established pathways to physical dependence.

The failure to adequately warn about dependence had cascading consequences. Physicians prescribed gabapentin freely, believing it was non-habit-forming. Patients were not counseled about the importance of gradual tapering. Insurance companies and pharmacy benefit managers imposed quantity limits and prior authorization requirements that sometimes forced abrupt discontinuation. And when states began scheduling gabapentin as a controlled substance — recognizing the dependence risk that the manufacturer had minimized — patients and physicians were caught off-guard by withdrawal symptoms they had been told would not occur.

State Scheduling and Controlled Substance Status

As evidence of gabapentin misuse potential and physical dependence accumulated, individual states began scheduling gabapentin as a controlled substance. As of 2026, states including Ohio, Kentucky, West Virginia, Tennessee, Alabama, Minnesota, Virginia, and Wisconsin have classified gabapentin as a Schedule V controlled substance, the least restrictive controlled substance category. This scheduling imposes prescription monitoring, limits on refills, and tracking through state prescription drug monitoring programs. The fact that states took regulatory action to control gabapentin distribution undermines the manufacturer's historical messaging that the drug was non-addictive and safe for long-term use.

Ironically, controlled substance scheduling has created additional withdrawal risks. Prior to scheduling, patients could easily obtain gabapentin refills, including from emergency departments and urgent care clinics. After scheduling, refill processes became more complex, and patients in some states experienced gaps in supply that led to involuntary abrupt discontinuation. These administrative disruptions — a foreseeable consequence of the late recognition of gabapentin's dependence potential — have produced additional withdrawal injuries that trace back to the manufacturer's decades of downplaying the drug's dependence risk.

Building a Withdrawal-Related Claim

Withdrawal-related gabapentin claims can stand alone or supplement cognitive decline claims. Standalone withdrawal claims arise when patients suffered seizures, emergency hospitalizations, or other acute withdrawal injuries during discontinuation. Supplemental withdrawal claims add damages to cognitive decline cases by documenting the additional harm caused by forced continuation during tapering and the withdrawal symptoms experienced during discontinuation. Evidence for withdrawal claims includes emergency department records for seizure events, documentation of tapering protocols and complications, pharmacy records showing gaps in supply that triggered withdrawal, and medical records documenting withdrawal symptoms and their duration.